Demand Diagnosis
Demand Diagnosis
Independent practice-transaction data shows US veterinary clinic visits falling for four straight years, yet Zoetis grew its US companion-animal business through that decline by expanding therapeutic categories and lifting spend per visit. In the first quarter of 2026 that offset broke: visits fell across every major therapeutic area at the same moment competition and pet-owner price sensitivity peaked, and US companion revenue dropped 11%. The evidence leans structural, with a real transient overlay; the direction of therapeutic-visit volume through 2026 is what separates the two.
The decoupling that carried US growth
For most of the last decade Zoetis's US story ran on a quiet decoupling: clinic foot traffic was soft, but the company's revenue climbed anyway. The mechanism had two parts. Pet owners who did visit spent more — in the first quarter of 2024, total vet clinic visits fell 1.5% while revenue and spend per visit rose 4.5% and 6% [1]. And the therapeutic visits that matter most to Zoetis grew even as wellness visits shrank: in the fourth quarter of 2024 dermatology visits rose 4% and pain-related visits rose 15%, so clinic revenue grew 7% on a per-visit basis "despite declining visits overall," and US companion-animal revenue grew 7% [2].
New product cycles did the rest of the work. Simparica Trio grew 61% in the US in the first quarter of 2024, and dermatology grew 27%, each expanding its category faster than clinic traffic contracted [3]. This is the innovation-led growth mechanism the moat produced (Franchise Moat): innovation created new demand faster than a maturing clinic channel eroded it.
Sources: Q1 2024 transcript [4]; Q4 2024 transcript [5]; Q3 2025 transcript [6]; Q1 2026 transcript [7].
Where the mechanism broke
The offset held until the therapeutic-visit growth that powered it reversed. In the third quarter of 2025, management noted declining visits "across all major therapeutic areas," which cut into new patient starts, and US companion-animal revenue went flat [8]. By the first quarter of 2026 the reversal was full: US companion-animal revenue fell 11%, with dermatology down 13%, the Simparica franchise down 8%, and osteoarthritis-pain antibodies down 15% [9].
US companion animal
US dermatology
US Simparica
US OA-pain mAbs
Q1 2026 US revenue, year-over-year. Source: Q1 2026 transcript [10].
What made the quarter different from prior competitive cycles was that the categories themselves stopped growing. Management put it plainly: "Unlike prior competitive cycles, we do not currently have the benefit of underlying market expansion to cushion the revenue effect of competitive share shifts," with dermatology facing "a derm market with declining patient volume in the clinic" and parasiticides showing "market contraction with softness in the clinics driven by lower flea tick and heartworm visits" [11]. For the first time, competitors' share gains came directly out of Zoetis's revenue rather than out of a bigger pie — and generics reached two companion-animal blockbusters, Convenia and Cerenia, that had not faced them before [12]. Management's own summary was that growth "is less driven by new product cycles" as it bridges to the next innovation wave [13].
Cyclical or structural
Part of the first-quarter collapse is genuinely transient. Winter storms cut clinic visits, distributor and retail partners drew down inventory instead of replenishing, and a fiscal-year alignment shifted roughly $100 million of international sales out of the prior quarter — without which the global organic decline would have been 5% rather than a headline distorted by timing [14], [15]. Comparisons ease as the year progresses, and management reports early stabilization: US Librela revenue rose sequentially for the first time in six quarters [16]. Management also frames the demand as delayed rather than lost, pointing to an estimated 11 million US dogs untreated or undertreated for itch alone [17].
The structural signal is harder to wave off, and it is not Zoetis's own number. Independent transaction data from Vetsource, covering roughly 6,500 US practices, shows US veterinary visits declining every year — down 3.5% in 2022, 1.4% in 2023, 2.6% in 2024, and 3.1% in 2025 — with the discretionary wellness end of the visit spectrum falling fastest. The interval between client visits stretched by nearly half between 2020-21 and 2023-24. And the price sensitivity Zoetis cites is deepening across the industry: a 2025 Gallup and PetSmart Charities study found 52% of US pet owners had skipped or declined veterinary care, most citing cost, and an AVMA-referenced survey found 81% of veterinarians reporting clients more cost-sensitive than a year earlier. This is a multi-year, market-wide erosion of clinic traffic that predates Zoetis's 2026 stumble.
US veterinary visit volume, year-over-year change; independent practice-transaction data (Vetsource white papers, April 2025 and January 2026). Not a Zoetis disclosure.
Zoetis's earlier framing shows how much the ground has moved. In 2022, a 4% visit decline was dismissed as a hard comparison against "unprecedented levels," with the industry judged "structurally and fundamentally in good shape" [18]; in early 2023 US clinic visits were still rising 2% [19]. What was cyclical noise then has settled into a persistent downtrend.
A useful control sits inside Zoetis's own results. In international markets where the standard of care is still maturing, that mechanism still works: international companion-animal revenue grew 7% in the first quarter of 2026, and the international Simparica franchise grew 14%, precisely because those categories are still expanding [20]. The engine is not broken; the US categories it feeds on have matured. The broader demand drivers management leans on — rising pet ownership, longer-lived pets, a deepening human-animal bond — remain intact in the filings [21], but they describe a slower, more contested US market than the one that produced the last decade of double-digit growth.
The read
The weight of evidence points to a structural shift in the US companion-animal market rather than a single-quarter air pocket. That decoupling worked because innovation expanded categories faster than clinic traffic fell; in 2026 that offset ran out just as competition intensified and macro caution deepened, and the market-wide visit data says the traffic erosion is secular, not seasonal. That said, this is a matter of degree, not a broken franchise: the same engine still compounds internationally, the untreated-patient runway is real, and a meaningful slice of the first quarter was storms, destocking, and calendar timing that will not repeat. The strongest fact against the structural read is that early stabilization is already visible and comparisons ease through 2026.
What would decide it is category volume, not share. If therapeutic-visit growth in dermatology and pain returns to positive as comparisons ease in the back half of 2026, the cyclical case holds and the offset resumes. Another year of declining category volumes — with share losses landing on a shrinking base — would confirm that the US growth algorithm has structurally slowed, and would put more weight on the 2027-2028 innovation wave management is pointing to, a pipeline it describes as 12 potential blockbusters, to re-expand categories that are no longer growing on their own [22].